Accepted answer
Start with the timing, because telogen effluvium has a characteristic delay of two to four months between the trigger and the shed.
The trigger in this context is the rate of weight loss and the associated nutritional deficit, not a pharmacological property. The same phenomenon is well documented after bariatric surgery, illness and childbirth.
Gastrointestinal adverse events, indicative pooled rates
| Event | Active arm | Placebo arm | Timing |
|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Specifically, nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.
The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.
Check ferritin, thyroid and vitamin D once, then stop investigating.
2The red-flag list should be higher up the answer, not at the bottom. – laminar_bench 7 months ago 3Worth adding that the area postrema explanation also predicts why it settles. – marta_szymanska 8 months ago add a comment